Cough syrup contaminated with DEG has caused ARI and the death of many children in The Gambia.

Published Date: 06 Mar 2023

USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...

Read Full News

Latest News

Understanding Atacicept & 36-Week ORIGIN 3 Data from Kidney Week 2025, With Jonathan Barratt, MBChB, PhD Jonathan Barratt, MBChB, PhD, FRCP

Jonathan Barratt, MBChB, PhD, discusses 36-week atacicept data from ASN Kidney Week 2025.

Telitacicept Achieves Primary Endpoint in IgA Nephropathy Phase 3 Study

Telitacicept Achieves Primary Endpoint in IgA Nephropathy Phase 3 Study

Pre-Conception Hypertension Linked to Adverse Pregnancy Outcomes in IgA Nephropathy

Pre-Conception Hypertension Linked to Adverse Pregnancy Outcomes in IgA Nephropathy

Gross Hematuria After COVID Vaccination Linked to Short-Term Kidney Function Decline in IgAN Abigail Brooks, MA

Increases in short-term kidney function decline were observed following post-COVID-19 vaccination gross hematuria in individuals with IgA nephropathy.

Navigating Treatment Decisions In IgAN, With Jai Radhakrishnan, MD Jai Radhakrishnan, MD

Radhakrishnan emphasizes the importance of individualized IgAN care and how to best use currently available and emerging treatments.

APPEAR-C3G: Iptacopan Shows Proteinuria Reduction, eGFR Benefits in C3G Abigail Brooks, MA

The phase 3 data reinforce iptacopan’s safety and efficacy in C3G and support its recent US Food and Drug Administration approval for this indication.

Todays Updates

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Todays Updates

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Latest News

Jonathan Barratt, MBChB, PhD, discusses 36-week atacicept data from ASN Kidney Week 2025.

Telitacicept Achieves Primary Endpoint in IgA Nephropathy Phase 3 Study

Pre-Conception Hypertension Linked to Adverse Pregnancy Outcomes in IgA Nephropathy

Increases in short-term kidney function decline were observed following post-COVID-19 vaccination gross hematuria in individuals with IgA nephropathy.

Radhakrishnan emphasizes the importance of individualized IgAN care and how to best use currently available and emerging treatments.

The phase 3 data reinforce iptacopan’s safety and efficacy in C3G and support its recent US Food and Drug Administration approval for this indication.

News All Time

5 Nephrology Headlines You Missed in October 2025 Alex Hillenbrand

October brings FDA approvals, new KDIGO guidance, and diagnostic breakthroughs

FDA Approves Kygevvi, First Treatment for Thymidine Kinase 2 Deficiency Alex Hillenbrand

The FDA has approved Kygevvi (doxycitine and doxribtimine), the first therapy to improve functional outcomes and survival in thymidine kinase 2 deficiency.

FDA Grants Orphan Drug Designation to ABBV-CLS-628 for ADPKD Alex Hillenbrand

ABBV-CLS-628, an anti–PAPP-A monoclonal antibody, earns Orphan Drug Designation, advancing through phase 2 testing for ADPKD.

Kidney Week 2025: ORIGIN 3 Sets the Stage for Atacicept in IgA Nephropathy Patrick Campbell

Phase 3 trial results reveal atacicept significantly reduces proteinuria in IgA nephropathy, paving the way for potential FDA approval in 2026.

FINE-ONE: Finerenone Proves Benefit in Type 1 Diabetes and CKD Patrick Campbell

Finerenone significantly reduces UACR in type 1 diabetes patients with chronic kidney disease, offering new hope for treatment.

Anxiety, Depression Linked to Poor Sleep Quality in ESRD Patients on HD Alex Hillenbrand

Findings showed anxiety, depression, and sleep disorders were highly prevalent among ESRD patients undergoing maintenance hemodialysis

Almost All Adults With Hypertensive CKD Would Benefit From Lower Blood Pressure Target

Almost All Adults With Hypertensive CKD Would Benefit From Lower Blood Pressure Target

PISCES: Fish Oil Slashes Cardiovascular Event Risk of Maintenance Dialysis Victoria Johnson

New data on daily fish oil supplementation prompts discussions on clinical recommendations.

DUPLEX: Sparsentan Outperforms Irbesartan in Reaching Key Proteinuria Threshold in FSGS Victoria Johnson

New findings reveal sparsentan significantly reduces proteinuria in FSGS patients, offering hope for improved kidney health and lower failure risk.

BESTOW: Tegoprubart Showcases Safer Prevention of Kidney Transplant Rejection Over Tacrolimus Victoria Johnson

Tegoprubart shows promise as a safer alternative to tacrolimus in kidney transplants, enhancing graft function with fewer side effects.

Younger Age at Glomerular Disease Diagnosis Linked to Greater Lifetime Risk Despite Similar Progression Rates

Younger Age at Glomerular Disease Diagnosis Linked to Greater Lifetime Risk Despite Similar Progression Rates

Sibeprenlimab Safely Reduces Gd-IgA1, Other IgAN Markers, in New Analysis

Sibeprenlimab Safely Reduces Gd-IgA1, Other IgAN Markers, in New Analysis

Uptrend in Acute Kidney Injury Mortality in Higher Socioeconomic Countries Projected to Continue

Uptrend in Acute Kidney Injury Mortality in Higher Socioeconomic Countries Projected to Continue

FDA Clears IND Application for EGEN-2784, a Genetically Engineered Pig Kidney, for ESKD

FDA Clears IND Application for EGEN-2784, a Genetically Engineered Pig Kidney, for ESKD

Hypertensive Kidney Disease Death Rate Up 48% in Past 25 Years

Hypertensive Kidney Disease Death Rate Up 48% in Past 25 Years

6 Nephrology Headlines You Missed in August 2025

6 Nephrology Headlines You Missed in August 2025

Recommended News For You

New Zealand and Australian breast cancer rates among the highest in the world, global study finds

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

Sydney researchers identify new tools to improve cancer diagnosis and treatment.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?

Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024

Using AI, one can find cancer risk factors.

Recommended Articles For You

Chondroma: What it is and How it Affects Your Health  

Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation 

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology 

Future of Chemotherapy: New Advances, Treatments & Survival Rates Transforming Cancer Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

2.

New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

3.

The FDA Approves the New Frontline Aggressive ALL Regimen.

4.

Childhood brain tumors develop early in highly specialized nerve cells, research reveals

5.

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

1.

Decoding Granular Cell Tumor: What You Need to Know

2.

Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer

3.

Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia

4.

Unlocking the Power of Cryoprecipitate: A Comprehensive Guide

5.

Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

5.

Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot